Correction: Azithromycin for acute exacerbations of Asthma: The AZALEA randomized clinical trial (JAMA Internal Medicine (2016) 176:11 (1630-1637) DOI: 10.1001/jamainternmed.2016.5664);Azithromycin for acute exacerbations of asthma: The AZALEA randomized clinical trial

JAMA Internal Medicine

Volumn 176, Issue 11, 2016, Pages 1630-1637

  Johnston, Sebastian L ^a   Szigeti, Matyas ^b   Cross, Mary ^b   Brightling, Christopher ^c   Chaudhuri, Rekha ^d,e   Harrison, Timothy ^f   Mansur, Adel ^g,h   Robison, Laura ^b   Sattar, Zahid ^b   Jackson, David ^a   Mallia, Patrick ^a   Wong, Ernie ^a   Corrigan, Christopher ^i,j   Higgins, Bernard ^k   Ind, Philip ^a,l   Singh, Dave ^m   Thomson, Neil C ^d   Ashby, Deborah ^b   Chauhan, Anoop ⁿ  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF LEICESTER   (United Kingdom)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

^e NHS GREATER GLASGOW AND CLYDE   (United Kingdom)

^f UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^g UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^h UNIVERSITY OF BIRMINGHAM   (United Kingdom)

ⁱ KING'S COLLEGE LONDON   (United Kingdom)

^j GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^k NEWCASTLE UNIVERSITY   (United Kingdom)

^l IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^m UNIVERSITY OF MANCHESTER   (United Kingdom)

ⁿ PORTSMOUTH HOSPITALS NHS TRUST   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CORTICOSTEROID; PLACEBO; ANTIINFECTIVE AGENT;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; ASTHMA; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DETERIORATION; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; EFFECT SIZE; EMERGENCY CARE; FEMALE; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICAL CARE; MEDICAL HISTORY; MULTICENTER STUDY; PRIORITY JOURNAL; QUALITY OF LIFE ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; STANDARD; SYSTEMIC THERAPY; TREATMENT DURATION; ADOLESCENT; BACTERIAL INFECTIONS; CLINICAL TRIAL; DISEASE COURSE; EMERGENCY HEALTH SERVICE; MIDDLE AGED; QUALITY OF LIFE; TREATMENT OUTCOME; UNITED KINGDOM;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; ASTHMA; AZITHROMYCIN; BACTERIAL INFECTIONS; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; EMERGENCY MEDICAL SERVICES; FEMALE; HUMANS; MALE; MIDDLE AGED; QUALITY OF LIFE; TREATMENT OUTCOME; UNITED KINGDOM;

EID: 84996487059     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamainternmed.2018.2967     Document Type: Erratum

References (37)

1. Weiss KB, Sullivan SD. The health economics of asthma and rhinitis. I. assessing the economic impact. J Allergy Clin Immunol. 2001;107(1):3-8.
2. Rabe KF, Vermeire PA, Soriano JB, MaierWC. Clinical management of asthma in 1999: The Asthma Insights and Reality in Europe (AIRE) study. Eur Respir J. 2000;16(5):802-807.
3. Johnston SL, Pattemore PK, Sanderson G, et al. Community study of role of viral infections in exacerbations of asthma in 9-11 year old children. BMJ. 1995;310(6989):1225-1229.
4. Chauhan AJ, Inskip HM, Linaker CH, et al. Personal exposure to nitrogen dioxide (NO2) and the severity of virus-induced asthma in children. Lancet. 2003;361(9373):1939-1944.
5. Johnston SL, Pattemore PK, Sanderson G, et al. The relationship between upper respiratory infections and hospital admissions for asthma: A time-trend analysis. Am J Respir Crit Care Med. 1996;154(3, pt 1):654-660.
6. Wark PA, Johnston SL, Moric I, Simpson JL, HensleyMJ, Gibson PG. Neutrophil degranulation and cell lysis is associated with clinical severity in virus-induced asthma. Eur Respir J. 2002;19(1):68-75.
7. Grissell TV, Powell H, Shafren DR, et al. Interleukin-10 gene expression in acute virus-induced asthma. Am J Respir Crit Care Med. 2005;172(4):433-439.
8. Wark PA, Johnston SL, Simpson JL, HensleyMJ, Gibson PG. Chlamydia pneumoniae immunoglobulin A reactivation and airway inflammation in acute asthma. Eur Respir J. 2002;20(4):834-840.
9. Esposito S, Blasi F, Arosio C, et al. Importance of acute Mycoplasma pneumoniae and Chlamydia pneumoniae infections in children with wheezing. Eur Respir J. 2000;16(6):1142-1146.
10. Cunningham AF, Johnston SL, Julious SA, Lampe FC,Ward ME. Chronic Chlamydia pneumoniae infection and asthma exacerbations in children. Eur Respir J. 1998;11(2):345-349.
11. Johnston SL, Martin RJ. Chlamydophila pneumoniae and Mycoplasma pneumoniae: A role in asthma pathogenesis? Am J Respir Crit Care Med. 2005;172(9):1078-1089.
12. Johnston SL, Blasi F, Black PN, Martin RJ, Farrell DJ, Nieman RB; TELICAST Investigators. The effect of telithromycin in acute exacerbations of asthma. N Engl J Med. 2006;354(15):1589-1600.
13. Talbot TR, Hartert TV, Mitchel E, et al. Asthma as a risk factor for invasive pneumococcal disease. N Engl J Med. 2005;352(20):2082-2090.
14. Klemets P, LyytikäinenO, Ruutu P, et al. Risk of invasive pneumococcal infections amongworking age adults with asthma. Thorax. 2010;65(8):698-702.
15. Pilishvili T, Zell ER, Farley MM, et al. Risk factors for invasive pneumococcal disease in children in the era of conjugate vaccine use. Pediatrics. 2010;126 (1):e9-e17.
16. Jounio U, Juvonen R, Bloigu A, et al. Pneumococcal carriage is more common in asthmatic than in non-asthmatic young men. Clin Respir J. 2010;4(4):222-229.
17. HiltyM, Burke C, Pedro H, et al. Disordered microbial communities in asthmatic airways. PLoS One. 2010;5(1):e8578.
18. Message SD, Laza-Stanca V, Mallia P, et al. Rhinovirus-induced lower respiratory illness is increased in asthma and related to virus load and Th1/2 cytokine and IL-10 production. Proc Natl Acad Sci U S A. 2008;105(36):13562-13567.
19. Contoli M, Message SD, Laza-Stanca V, et al. Role of deficient type III interferon-λ production in asthma exacerbations. Nat Med. 2006;12(9):1023-1026.
20. Oliver BG, Lim S,Wark P, et al. Rhinovirus exposure impairs immune responses to bacterial products in human alveolar macrophages. Thorax. 2008;63(6):519-525.
21. Avadhanula V, Rodriguez CA, Devincenzo JP, et al. Respiratory viruses augment the adhesion of bacterial pathogens to respiratory epithelium in a viral species-and cell type-dependent manner. J Virol. 2006;80(4):1629-1636.
22. Bisgaard H, Hermansen MN, Bønnelykke K, et al. Association of bacteria and viruses with wheezy episodes in young children: prospective birth cohort study. BMJ. 2010;341:c4978.
23. British Thoracic Society; Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma. Thorax. 2008;63(suppl 4): iv1-iv121.
24. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention (2015 Update). http://ginasthma.org/wp-content/uploads/2016/01/GINA-Report-2015-Aug11-1.pdf. Accessed July 1, 2016.
25. Kobayashi Y,Wada H, Rossios C, et al. A novel macrolide solithromycin exerts superior anti-inflammatory effect via NF-κB inhibition. J Pharmacol Exp Ther. 2013;345(1):76-84.
26. Gielen V, Johnston SL, Edwards MR. Azithromycin induces anti-viral responses in bronchial epithelial cells. Eur Respir J. 2010;36(3): 646-654.
27. Wark PA, Johnston SL, Bucchieri F, et al. Asthmatic bronchial epithelial cells have a deficient innate immune response to infection with rhinovirus. J Exp Med. 2005;201(6):937-947.
28. British Thoracic Society; Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma. Thorax. 2014;69(suppl 1):1-192.
29. Zeitlinger M,Wagner CC, Heinisch B. Ketolides-the modern relatives of macrolides: The pharmacokinetic perspective. Clin Pharmacokinet. 2009;48(1):23-38.
30. Walsh F, Carnegy F, Willcock J, Amyes S. Comparative in vitro activity of telithromycin against macrolide-resistant and-susceptible Streptococcus pneumoniae, Moraxella catarrhalis and Haemophilus influenzae. J Antimicrob Chemother. 2004;53(5):793-796.
31. Kosowska K, Credito K, Pankuch GA, et al. Activities of two novel macrolides, GW773546 and GW708408, compared with those of telithromycin, erythromycin, azithromycin, and clarithromycin against Haemophilus influenzae. Antimicrob Agents Chemother. 2004;48(11):4113-4119.
32. De Vecchi E, Nicola L, Larosa M, Drago L. In vitro activity of telithromycin against Haemophilus influenzae at epithelial lining fluid concentrations. BMC Microbiol. 2008;8:23.
33. Leung E,Weil DE, Raviglione M, Nakatani H; World Health OrganizationWorld Health Day Antimicrobial Resistance TechnicalWorking Group. The WHO policy package to combat antimicrobial resistance. BullWorld Health Organ. 2011;89(5): 390-392.
34. Beigelman A, Isaacson-Schmid M, Sajol G, et al. Randomized trial to evaluate azithromycin's effects on serum and upper airway IL-8 levels and recurrent wheezing in infants with respiratory syncytial virus bronchiolitis. J Allergy Clin Immunol. 2015;135(5):1171-1178.e1.
35. Stokholm J, Chawes BL, Vissing NH, et al. Azithromycin for episodes with asthma-like symptoms in young children aged 1-3 years: A randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2016;4(1):19-26.
36. Bacharier LB, Guilbert TW, Mauger DT, et al; National Heart, Lung, and Blood Institute's AsthmaNet. Early administration of azithromycin and prevention of severe lower respiratory tract illnesses in preschool children with a history of such illnesses: A randomized clinical trial. JAMA. 2015; 314(19):2034-2044.
37. Brusselle GG, Vanderstichele C, Jordens P, et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): A multicentre randomised double-blind placebo-controlled trial. Thorax. 2013; 68(4):322-329.